Recent Insider Transactions • 14h
Chief Financial Officer recently bought kr110k worth of stock On the 17th of July, Holger Lembrer bought around 50k shares on-market at roughly kr2.20 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Holger's only on-market trade for the last 12 months. Reported Earnings • Jul 17
Second quarter 2026 earnings released: kr0.053 loss per share (vs kr0.06 loss in 2Q 2025) Second quarter 2026 results: kr0.053 loss per share (improved from kr0.06 loss in 2Q 2025). Revenue: kr7.15m (down 14% from 2Q 2025). Net loss: kr13.0m (loss narrowed 10% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Jun 24
Enzymatica AB (publ) Provides Update On The Evidence Base For Coldzyme And PLOS ONE Expression Of Concern Regarding Berlin II Article Enzymatica AB (publ) noted that the scientific journal PLOS ONE has published an Expression of Concern regarding an article on the Berlin II study from 2023. The notice is not a retraction. The article remains published. The scientific evidence base for ColdZyme – including the independent Davison study from 2025 – remains unchanged. The same applies to the regulatory position. PLOS notice concerns how certain exploratory analyses and wording were presented in the 2023 Berlin II article, rather than the conduct of the study or the validity of the underlying data. The primary endpoint in Berlin II was not met – as clearly stated in the published article. Nevertheless, the study included 438 randomized participants, of whom 220 were in the ColdZyme group, and contributes important safety and tolerability data in a large population. Davison et al. (2025), conducted at the University of Kent, is an independent, randomized and peer-reviewed clinical study that demonstrated statistically significant effects across several key endpoints related to upper respiratory tract infections. The Davison study is not affected by PLOS ONE’s questions regarding the Berlin II article. Enzymatica’s marketing claims for ColdZyme are based on a broader scientific foundation than the Berlin II article from 2023, including preclinical research, mechanistic data and several clinical studies, including Davison 2025. At present, PLOS ONE’s notice does not prompt any changes to the company’s marketing, clinical evaluation report (CER), Summary of Safety and Clinical Performance (SSCP), or regulatory status. ColdZyme is a clinically documented medical device mouth spray for colds and cold-like symptoms and is certified under the EU regulatory framework for medical devices, MDR Class III. The product was recently named best in test among cold sprays by the independent Swedish consumer guide Bäst-i-Test.se. An Expression of Concern is an editorial tool used by scientific journals to signal that a question has arisen regarding an article, without retracting the article. The article remains published and citable. 
